Related Experiment Video

Updated: Apr 1, 2026

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.7K

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway

Wade T Iams1, Christine M Lovly2

  • 1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 3, 2015
PubMed

Insights

Targeting the Insulin-like Growth Factor 1 Receptor (IGF1R) pathway shows promise in sarcoma but faces challenges in breast cancer and non-small cell lung cancer (NSCLC). Identifying predictive biomarkers is crucial for effective IGF1R-directed therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Insulin-like Growth Factor 1 Receptor (IGF1R) signaling pathway regulates cell proliferation, growth, and survival.
  • IGF1R is a significant therapeutic target for various malignancies.
  • Clinical trials have investigated IGF1R pathway inhibition across multiple cancer types.

Purpose of the Study:

  • To review clinical trial outcomes targeting the IGF1R pathway in breast cancer, sarcoma, and non-small cell lung cancer (NSCLC).
  • To discuss various therapeutic agents, including monoclonal antibodies and small-molecule inhibitors.
  • To highlight the need for predictive biomarkers to guide IGF1R-directed therapy selection.

Main Methods:

  • Review of clinical trial data for IGF1R-targeted agents.
  • Analysis of therapeutic strategies including monoclonal antibodies (e.g., dalotuzumab, figitumumab) and small-molecule inhibitors (e.g., linsitinib).
  • Examination of various biomarkers such as tumor IGF1R expression and serum ligand levels.

Main Results:

  • IGF1R inhibitor monotherapy demonstrated sustained success in a subset of sarcoma patients.
  • Clinical trials in breast cancer and NSCLC were largely discontinued due to negative outcomes.
  • Biomarker studies showed variable success, indicating a need for improved predictive markers.

Conclusions:

  • The efficacy of IGF1R-targeted therapies varies significantly across different cancer types.
  • Identifying predictive biomarkers is essential for patient selection and optimizing treatment outcomes.
  • Ongoing research aims to uncover resistance mechanisms and discover effective biomarkers for IGF1R-directed therapies.

More Related Videos

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay08:34

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

766
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K